Introducing Junevity: Cell Reset for Longevity with siRNA
Co-founders John Hoekman, Janine Sengstack, Rob Cahill
Today is another step towards longer, healthier lives.
It all started back in 2017 when Janine’s PhD advisor at UCSF, Dr. Hao Li, asked her, “I have an idea for a PhD project for you to lead… but it’s high risk. Would you be interested?”
With much hesitation, Janine said, “Yes!”
Today, we are thrilled to announce Junevity has raised our first $10M of VC Seed funding to develop Cell Reset therapeutics for longevity. Our science and platform is based on Janine’s PhD work with Hao and the Li Lab.
We make siRNA therapeutics targeting transcription factors. This approach is powerful. Transcription factors regulate broad-based gene expression. Targeting transcription factors with therapeutics can lead to reversing cellular damage caused by aging and disease. Breakthroughs in genomics, AI and siRNA make this possible. In fact, this only was possible to even consider during Janine’s PhD from 2017-2023.
We’ve all experienced the suffering, pain and loss of age-related disease in people close to us. We believe science, AI and human ingenuity can fix this.
John and Rob are both second-time founders, with John’s first company earning FDA approval for Trudhesa for migraines and Rob’s successfully acquired by FranklinCovey (NYSE: FC). When looking for their next venture, they both wanted a big idea that could change the future of human health.
Junevity is that idea.
You can read more about our funding announcement here, as well coverage from Longevity.Technology (here) and Endpoints News (here, paywall).
Please consider following us and sharing the news on LinkedIn or X (@Junevity).